Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone?
This week: an observational study of microdosers published last week has encouraged healthy debate; COMPASS Pathways secures its fifth US patent; op-ed on the ecological and cultural damage associated with the pursuit of toad secretions; and more…
Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing Study; Shorter Trips?
This week: The U.S. Drug Enforcement Administraion has once again increased quotas on psychedelics production; MindMed announces a new microdosing study on sleep and cognition; are shorter trips the route to payer acceptance?; and more…
Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results
This week: we take a deep dive into COMPASS Pathways’ topline Phase 2b results released last Tuesday…
Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin
This week: We speak to Rick Doblin about recent psychedelic drug development announcements; COMPASS Pathways targets PTSD; Detroit becomes latest U.S. city to decriminalize psychedelics; and more…
Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures Ethics Approval; UCL Joins the Renaissance
This week: MindMed revealed its latest program, which is looking to develop R(-)-MDMA for social anxiety associated with autism; Austalian psilocybin for anxiety study gets ethics approval; UCL launches psychedelics and neuroplasticity project; and more…
Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data
This week: London-based Small Pharma’s DMT candidate fast-tracked by regulators; COMPASS secures fourth patent and shares group therapy data; Boris Johnson to consider rescheduling psilocybin; and more…